explore -WSS

explore

author：leisure time 2025-09-29 17:52:53 - browse：3

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： As Maui death toll rises, number of missing remains unclear

entertainment

WSS

Why we need to separate burnout from moral injury in health care

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Why we need to separate burnout from moral injury in health care

FDA approves first treatment for ultra

Disclosing genetic information: not as worrisome as once feared

Why we need to separate burnout from moral injury in health care

focus

explore

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Why drug prescriptions should include diagnoses

Alkermes shareholders re

CDC concerned about possible undetected monkeypox spread in U.K.

After affirmative action ruling, medical educators look to 'holistic review'

FDA approves first treatment for ultra

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Virginia high school admissions case could be legal follow

Lung cancer is America's deadliest cancer. Yet so few get screened

entertainment

Cloning humans is technically possible. It's curious no one has tried

Do masks work? RCTs can't tell us

Living with Hashimoto's and celiac disease, and med school, too

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Weight bias in eating disorder treatment complicated by new weight loss drugs

Death of patient in Alzheimer’s trial raises question of possible risks

entertainment

knowledge

focus

focus